Evidence map›Paper›PMID 40058709›Full record

Trial reportInternational journal of radiation oncology, biology, physics2025

A Phase 2 Study of Multiparametric Magnetic Resonance Imaging-Guided High-Dose Response-Adaptive Radiation Therapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma: Results From an Interim Analysis.

Michelle M Kim, Madhava P Aryal, Krithika Suresh, Benjamin S Rosen, Hemant Parmar, Daekeun You, Denise Leung, Nathan Clarke, John Fortunato, Wajd Al-Holou and 7 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04574856 (A Phase II Study of Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04574856 phase2active not recruitingnot on this map

A Phase II Study of Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

TypeinterventionalSponsorUniversity of Michigan Rogel Cancer CenterRan2020 to 2027Enrolled30ConditionsGlioblastomaArmsDose-Intensified Radiotherapy, Temozolomide, Adjuvant temozolomide
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Michelle M KimDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan. Electronic address: michekim@med.umich.edu.
Madhava P AryalDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan.
Krithika SureshDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan; Department of Biostatistics, The University of Michigan, Ann Arbor, Michigan.
Benjamin S RosenDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan.
Hemant ParmarDepartment of Radiology, The University of Michigan, Ann Arbor, Michigan.
Daekeun YouDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan.
Denise LeungDepartment of Neurology, The University of Michigan, Ann Arbor, Michigan.
Nathan ClarkeDepartment of Neurology, The University of Michigan, Ann Arbor, Michigan.
John FortunatoDepartment of Neurology, The University of Michigan, Ann Arbor, Michigan.
Wajd Al-HolouDepartment of Neurosurgery, The University of Michigan, Ann Arbor, Michigan.
Jason HethDepartment of Neurosurgery, The University of Michigan, Ann Arbor, Michigan.
David AltshulerDepartment of Neurosurgery, The University of Michigan, Ann Arbor, Michigan.
Todd HollonDepartment of Neurosurgery, The University of Michigan, Ann Arbor, Michigan.
Donna M EdwardsDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan.
Daniel R WahlDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan; Department of Neurosurgery, The University of Michigan, Ann Arbor, Michigan.
Theodore S LawrenceDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan.
Yue CaoDepartment of Radiation Oncology, The University of Michigan, Ann Arbor, Michigan; Department of Radiology, The University of Michigan, Ann Arbor, Michigan; Department of Biomedical Engineering, The University of Michigan, Ann Arbor, Michigan.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
TREATMENT VERIFICATION AND TREATMENT PLAN REFINEMENTP01CA059827 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAWRENCE, THEODORE S, TEN HAKEN, RANDALL K · 1993 to 2018
$37.9M
Dr. Kim R50 Research Specialist Clinician 2022R50CA276015 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Michelle Miran Kim · 2023 to 2026
$687k
NCI NIH HHS P01 CA059827NCI NIH HHS P30 CA046592NCI NIH HHS R50 CA276015
6 · The paper itself

Abstract

purposeBiologically-informed radiation therapy (RT) targeting an adversely prognostic hypercellular/hyperperfused imaging phenotype in patients with newly diagnosed glioblastoma (GBM) may improve outcomes by identifying emerging regions of treatment resistance associated with overall survival, and is under investigation in an ongoing phase 2 trial (NCT04574856) of individualized, response-adaptive RT. METHODS AND MATERIALS: In this single-arm phase 2 study, patients with newly diagnosed GBM after resection undergo dose-intensified chemoradiation targeting the residual hypercellular (TV

resultsAt interim analysis, 16 of 30 patients were enrolled. Median age was 58 years (range, 29-75) and 69% were male. No patient underwent biopsy only, and 50% had gross total resection; 19% had O

conclusionsIndividualized, response-adaptive chemoradiation using an advanced imaging biomarker to assess emerging and especially nonenhancing regions of treatment resistance in patients with GBM is feasible, with short-term safety and longer-term efficacy outcomes anticipated with completion of accrual.

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsChemoradiotherapyGlioblastomaMultiparametric Magnetic Resonance ImagingRadiotherapy, Image-GuidedTemozolomideAdultAgedFemaleHumansMaleMiddle AgedRadiotherapy DosageTumor BurdenAntineoplastic Agents, AlkylatingTemozolomide

Identifiers

PMID40058709
PMCPMC12146080

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.